奥西默替尼
GNAS复合轨迹
曲美替尼
T790米
医学
肺癌
肿瘤科
克里唑蒂尼
内科学
癌症研究
表皮生长因子受体
腺癌
吉非替尼
癌症
激酶
生物
MAPK/ERK通路
埃罗替尼
基因
遗传学
恶性胸腔积液
作者
You Li,Chao Zhou,Zhonghai Chen,Xinqing Zhao,Yuhan Sun,Jieyi Li,Zhongmiao Gong,Daoyuan Zhang,Hai Huang
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2022-08-09
卷期号:33 (9): 966-969
被引量:1
标识
DOI:10.1097/cad.0000000000001342
摘要
Osimertinib, an orally administered third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is widely approved for the first-line and second-line treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. However, the rapid development of osimertinib resistance renders the unsustainable treatment benefit. Patients with EGFR -mutated NSCLC who develop osimertinib resistance, especially those acquiring relatively rare and ‘off-target’ resistance mutations, still lack effective therapeutic options for postosimertinib therapy. Herein, we reported a 73-year-old woman diagnosed with T1N3M1 lung adenocarcinoma harboring EGFR L858R mutation, who acquired two GNAS mutations (R201C and R201H) and lost the EGFR L858R mutation after progression on icotinib and osimertinib. The patient was subsequently treated with trametinib and there was no obvious tumor increase. Our study revealed that GNAS R201 can confer the osimertinib resistance in EGFR -positive NSCLC, and present the first report of the prevalence of GNAS R201C and R201H mutants in NSCLC which response to trametinib treatment. Our case suggests that trametinib could be a treatment option in NSCLC patients harboring GNAS -activating mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI